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Abstract. The present study (KGOG 3030) aimed to evaluate 
the safety of modulated electro‑hyperthermia (mEHT) therapy 
with weekly administration of paclitaxel or cisplatin in female 
patients with recurrent or persistent epithelial ovarian, fallopian 
tube or primary peritoneal carcinoma. A total of 12 patients 
were randomized into the paclitaxel or cisplatin arm at a 
1:1 ratio. Patients received weekly administration of paclitaxel 
(70 mg/m2) or cisplatin (40 mg/m2) intravenously on days 1, 8 
and 15, and underwent mEHT therapy for 1 h on days 1, 4, 8, 11, 
15, 18, 21 and 24 for each 4‑week cycle. The primary endpoint 
was the occurrence of dose‑limiting toxicity (DLT). The 
secondary endpoints were treatment‑emergent adverse events 
(TEAEs), objective response rate, carbohydrate antigen 125 
(CA125) response rate, progression‑free survival (PFS) and 
overall survival (OS). In total, 16 patients were recruited, but 
four patients dropped out. None of the 12 remaining patients 
(6 each in the two arms) experienced DLT. Overall, 0 and 4 
grade 3 TEAEs (anemia, nausea, neutrophil count decreased 
and platelet count decreased) occurred in the paclitaxel and 
cisplatin arm, respectively. Furthermore, one confirmed partial 
response and two CA125 responses were observed in the cispl‑
atin arm. The median PFS time in the paclitaxel and cisplatin 
arms was 3.0 months (range, 1.7‑4.6 months) and 6.8 months 
(range, 3.9‑11.8 months), respectively, while the median OS 
time was 11.5 months (range, 8.4‑28.8+ months) and not 
reached (range, 3.9‑38.5+ months), respectively. In conclusion, 
mEHT therapy with weekly paclitaxel or cisplatin appeared 
safe and warrants further investigation. The present trial was 
registered with www.clinicaltrials.gov on January 22, 2015 
(trial registration no. NCT02344095).
Introduction
Recurrent ovarian cancer is incurable and, accordingly, has 
poor prognosis. In a study analyzing survival data from clinical 
trials of ovarian cancer, the median overall survival (OS) after 
the first, second, third, fourth and fifth recurrence was 17.6, 
11.3, 8.9, 6.2 and 5.0 months, respectively (1). Therefore, novel 
treatment options are urgently required for such patients. 
Radiofrequency hyperthermia (RFH) therapy involves heating 
of the body using radiofrequency energy. While it has been 
applied for the treatment of different cancer types, its efficacy 
remains conflicting. For instance, in a randomized trial of 
73 patients with advanced ovarian cancer, those who received 
chemotherapy with RFH achieved better tumor remission rates 
than those who received chemotherapy alone (2). However, in a 
randomized trial of patients with cervical cancer, there was no 
significant difference in survival between those who received 
RFH with radiotherapy and those who received radiotherapy 
alone. In addition, acute toxicity was significantly worse in the 
RFH plus radiotherapy arm (3).
Modulated electro‑hyperthermia (mEHT) is a type of 
RFH that uses impedance coupling with amplitude‑modulated 
13.56 MHz carrier radiofrequency (4). Similar to conventional 
RFH, mEHT is usually administered for 60 min, 1‑3 times 
per week (3,5‑7). However, unlike conventional RFH, the 
energy of radiofrequency is selectively absorbed by the tumor 
cells in mEHT (8). In addition, an in vitro study reported 
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that the cellular response to mEHT is different from that to 
conventional RFH. Specifically, in contrast to conventional 
RFH, mEHT activates caspase‑dependent pathways and 
induces apoptosis (9). Therefore, it was hypothesized that 
the oncologic effect of mEHT may be different from that of 
conventional RFH.
To the best of our knowledge, only 3 trials investigating 
the effects of mEHT therapy on cancer have been published to 
date. Although the trials were on different cancers, the results 
all suggested that the addition of mEHT was beneficial for 
achieving a higher response rate (5) and better local control (6) 
than conventional treatments and was highly feasible (7). 
However, evidence on the usefulness and safety of mEHT 
combined with chemotherapy in the treatment of ovarian 
cancer is currently lacking (10). Thus, the present study aimed 
to evaluate the safety of mEHT therapy with weekly paclitaxel 
or cisplatin administration in females with recurrent or persis‑
tent epithelial ovarian, fallopian tube or primary peritoneal 
carcinoma.
Materials and methods
Trial design and randomization. The present tr ial 
(KGOG 3030) was a phase 1 trial with 1 dose level performed 
at three tertiary hospitals (Seoul National University Bundang 
Hospital, Seongnam, Gyeonggi; Gangnam Severance 
Hospital, Seoul; Ewha Womans University Mokdong Hospital, 
Seoul) in the Republic of Korea between February 2015 and 
November 2017. The study was conducted according to the 
tenets of the Declaration of Helsinki and its later amendments, 
and the protocol was approved by the Institutional Review 
Board (IRB) of each hospital (Seoul National University 
Bundang Hospital IRB, approval no. E‑1407/258‑001, 
approval date 17th Sep 2014; Yonsei University Gangnam 
Severance Hospital IRB, approval no. 3‑2014‑0272, approval 
date 14th January 2015; Ewha Womans University Medical 
Center IRB, approval no. EUMC 2014‑09‑009, approval date 
1st December 2014) and registered at www.clinicaltrials.gov 
(on January 22, 2015; registration no. NCT02344095). Written 
informed consent was obtained from all subjects. The present 
study was reported in line with the Consolidated Standards of 
Reporting Trials guidelines (11).
There is already a widely used protocol for mEHT therapy 
and numerous cases in which mEHT therapy was combined 
with various chemotherapy modalities were encountered in 
our clinical practice. Therefore, the widely used protocol for 
mEHT therapy (1 h; 2 sessions per week; maximum energy, 
140 W) (10) was adopted. In addition, it was decided not to test 
several dose levels of chemotherapy and adopt a 3+3 design 
with only 1 dose level (70 mg/m2 for paclitaxel, 40 mg/m2 for 
cisplatin). Specifically, 3 patients were enrolled and underwent 
therapy with a dose level of chemotherapy plus mEHT. If 
dose‑limiting toxicity (DLT) was observed in <2 of 3 patients, 
3 more patients were enrolled. If DLT occurred in <2 of 
6 patients, it was concluded that the dose was safe enough for 
use in a further investigation. There was no dose escalation 
or de‑escalation. Therefore, the anticipated number of patients 
was 12 (6 in each arm).
The optimal chemotherapy drug to be combined with mEHT 
therapy in recurrent ovarian cancer has remained undetermined. 
In vitro studies suggested that hyperthermia potentiates the 
cytotoxic effects of cisplatin (12,13). Furthermore, weekly 
paclitaxel administration is an effective regimen in recurrent 
ovarian cancer (14). After a thorough review of the literature 
and discussion, paclitaxel and cisplatin were selected (12‑14). 
To determine which drug should be selected for further 
investigation at the completion of the present trial, both the 
paclitaxel and cisplatin arms were launched and compared using 
randomization. Patients were randomized into the paclitaxel 
arm or the cisplatin arm at a 1:1 ratio using block randomization 
with ‘hospital’ as a stratification factor. Randomization and 
notification of results were performed by the independent data 
center and the randomization result was not concealed.
Eligibility and intervention. The inclusion criteria were as 
follows: i) Recurrent or persistent epithelial ovarian, fallopian 
tube or primary peritoneal carcinoma; ii) tumor evaluable 
with radiologic study or serum carbohydrate antigen (CA)125; 
and iii) Eastern Cooperative Oncology Group performance 
status score (15) of 0‑2. The exclusion criteria were as follows: 
i) Tumor located in previously irradiated area; ii) brain 
metastasis; iii) residual neurotoxicity or history of severe 
neurotoxicity; iv) hypersensitivity to paclitaxel or cisplatin; 
and v) pacemaker or metal implants. The number of previous 
chemotherapy regimens was limited to <3 at initiation. 
However, due to slow accrual, the limit was changed to <4 in 
August 2015 and was removed in July 2016.
Patients in the paclitaxel arm received 4 cycles of mEHT 
therapy with weekly paclitaxel chemotherapy, with each 
cycle lasting 4 weeks. After steroids and anti‑histamines 
were administered to prevent infusion reactions, 70 mg/m2 
of paclitaxel was intravenously infused for 1 h on days 1, 8 
and 15 every 4 weeks. Within 3 h of completion of paclitaxel 
infusion, mEHT therapy was initiated. The mEHT therapy 
was performed 2 times weekly (days 1, 4, 8, 11, 15, 18, 21 and 
24 per cycle) using an EHY 2000 plus device (Oncotherm 
GmbH) and each mEHT therapy session lasted 60 min. During 
the mEHT therapy, patients were placed in a supine position 
and a 30‑cm diameter circular mEHT electrode was attached 
to the abdominal wall over the tumor. No precise targeting 
of the tumor was performed. Starting from 60 W, energy was 
gradually increased to 140 W. If the patient felt hot or had any 
discomfort, the energy was decreased to the previous level and 
then maintained at that level throughout the duration of the 
session. When tumors were present in the abdomen and chest 
area, mEHT therapy was performed sequentially (starting at 
the abdomen and then the chest).
Patients in the cisplatin arm received 4 cycles of mEHT 
therapy plus weekly cisplatin chemotherapy, with each cycle 
lasting 4 weeks; 40 mg/m2 of cisplatin was intravenously 
infused for 1 h on days 1, 8 and 15 every 4 weeks. The mEHT 
therapy protocol was the same as that for the paclitaxel arm.
Endpoints. The primary endpoint was the occurrence of DLT 
from enrollment to fourth cycle completion in evaluable patients 
of each arm. DLT was defined as the occurrence of any of the 
following: i) Neutropenic fever requiring inotropics or intensive 
care unit admission; ii) hematologic toxicity not recovered to 
grade 1 or 2 within 3 weeks (except anemia); iii) non‑hematologic 
toxicity not recovered to grade 1 or 2 within 3 weeks (except 
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alopecia); and iv) death. Evaluable patients were defined as 
patients who completed the second cycle.
The secondary endpoints were safety and preliminary 
efficacy. Safety was measured according to the type, grade 
and incidence of treatment‑emergent adverse events (TEAEs) 
evaluated using the Common Terminology Criteria for Adverse 
Events version 4.0 (16). The efficacy endpoints were objective 
response rate in patients with measurable disease as evaluated 
using the Response Evaluation Criteria in Solid Tumors 
version 1.1 (17), CA125 response rate in patients with elevated 
baseline CA125, progression‑free survival (PFS) and OS. The 
CA125 response was defined as a decrease of >50% from the 
baseline with confirming repeat test results. During treatment, 
physical examination and CA125 test were performed every 
cycle. After treatment was completed, patients were followed 
up every 3 months until death. CA125 and imaging tests were 
performed at the discretion of the physician
Statistical analysis. All statistical analyses were performed 
using SPSS version 25 (IBM Corp.). Continuous variables 
were presented as the median and range. Categorical variables 
were presented as counts and percentages. PFS and OS were 
estimated using the Kaplan‑Meier method. 
Results
Baseline characteristics. In total, 16 patients were recruited 
for the present study. A flowchart depicting the movement 
of the patients throughout the study is provided in Fig. 1. 
Of 16 patients, four patients in the cisplatin arm did not 
complete the first cycle and were not evaluable. The 
time‑point and reasons for treatment discontinuation of 
the 4 patients were as follows: Patient 1 (prior to cycle 1, 
withdrawal of consent), patient 2 (cycle 1 day 1, withdrawal 
of consent), patient 3 (cycle 1 day 15, clinical deterioration 
due to presumed cancer progression) and patient 4 (cycle 1 
day 8, withdrawal of consent). No TEAEs of grade 3 or 
above were observed in the 4 patients. The 4 patients were 
excluded from the efficacy and safety analysis according to 
the protocol.
The baseline characteristics of the 12 evaluable patients 
are summarized in Table I. The median age was 64 years and 
the high‑grade serous type was the most common histological 
type. The number of previous chemotherapy regimens ranged 
from 1 to 5 and most of patients were platinum‑resistant or 
refractory.
Safety. None of the 12 evaluable patients experienced 
DLT. No severe TEAE occurred in the paclitaxel arm. The 
common TEAEs were constipation, dyspepsia, headache and 
neutropenia. A total of, four grade‑3 TEAEs occurred in the 
cisplatin arm. These were grade‑3 anemia (n=1), nausea (n=1), 
neutropenia (n=1) and thrombocytopenia (n=1). The common 
TEAEs were neutropenia and nausea. TEAEs according 
to type and grade in the paclitaxel and cisplatin arms are 
summarized in Tables II and III, respectively.
Figure 1. Flowchart depicting the movement of patients throughout the present trial.
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Efficacy. Of the 12 patients, 9 patients (5 in the paclitaxel arm, 
4 in the cisplatin arm) had measurable disease at baseline. 
Of the 9 patients, 1 confirmed partial response was observed 
in the cisplatin arm (platinum‑resistant, high‑grade serous). 
The duration of response was 4 months. Furthermore, 9 of 
the 12 patients (4 in the paclitaxel arm, 5 in the cisplatin arm) 
had elevated baseline CA125 levels. Among them, 2 CA125 
responses (2 in the cisplatin arm, both were platinum‑resistant, 
high‑grade serous) were observed. The duration of response was 
4 and 10 months. Progression was observed in all patients. The 
median PFS in the paclitaxel and cisplatin arms was 3.0 months 
(range, 1.7‑4.6 months) and 6.8 months (range, 3.9‑11.8 months), 
respectively. At the cut‑off of September 12, 2018, 5 of the 
12 patients had died (4 in the paclitaxel arm, 1 in the cisplatin 
arm). The median OS in the paclitaxel and cisplatin arms was 
11.5 months (range, 8.4‑28.8+ months) and not reached (range, 
3.9‑38.5+ months), respectively (data not shown).
Discussion
In a previous study, chemotherapy combined with conventional 
RFH was reported to be more effective than chemotherapy 
alone for the treatment of advanced ovarian cancer (2). 
However, to the best of our knowledge, no previous study has 
examined the efficacy and safety of chemotherapy combined 
with mEHT for ovarian cancer. Therefore, the present study 
is novel and it is the first to examine the safety and efficacy 
of chemotherapy combined with mEHT for the treatment of 
ovarian cancer.
Table I. Baseline characteristics of the patients.
Variable Paclitaxel + mEHT (n=6) Cisplatin + mEHT (n=6)
Age, years 67 (53‑71) 61 (56‑72)
Body height, cm 155 (143‑163) 153 (149‑156)
Body weight, kg 60 (50‑64) 55 (47‑86)
Origin of cancer  
  Ovary 5 (83) 4 (67)
  Peritoneal 1 (17) 2 (33)
FIGO stage  
  3 4 (67) 5 (83)
  4 2 (33) 1 (17)
Histologic type  
  High‑grade serous 4 (67) 5 (83)
  Clear cell 1 (17) 0 (0)
  Low‑grade serous 0 (0) 1 (17)
  Carcinosarcoma 1 (17) 0 (0)
Number of previous regimens 2 (1‑4) 2 (1‑5)
Treatment‑free interval from previous treatment, months 5 (1‑16) 6 (0‑27)
Sensitivity to platinum  
  Sensitive 2 (33) 1 (17)
  Resistant 2 (33) 4 (67)
  Refractory 2 (33) 1 (17)
Values are expressed as the median (range) or n (%). mEHT, modulated electro‑hyperthermia; FIGO, International Federation of Gynecology 
and Obstetrics.
Table II. Treatment‑emergent adverse events in the paclitaxel arm.
Type Grade 1 Grade 2 Sum
Abdominal distension 1 0 1
Abdominal pain 0 1 1
Alopecia 1 0 1
Anorexia 0 1 1
Constipation 1 1 2
Creatinine increased 0 1 1
Dysarthria 0 1 1
Dyspepsia 2 0 2
Dyspnea 0 1 1
Fatigue 1 0 1
Flank pain 0 1 1
Headache 2 1 3
Hyperkalemia 1 0 1
Hypocalcemia 1 0 1
Neutrophil count decreased 0 2 2
Pain 1 0 1
Peripheral sensory neuropathy 0 1 1
Productive cough 1 0 1
Toothache 0 1 1
Tremor 0 1 1
Wound complication 1 0 1
Sum 13 13 26
Patients who experienced multiple treatment‑emergent adverse 
events were counted more than one time.
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The results of the present phase 1 trial indicated that 
mEHT therapy combined with weekly chemotherapy is safe 
enough to proceed to be investigated in further clinical trials. 
Specifically, no DLT occurred in both the paclitaxel and 
cisplatin arms, and only 4 grade 3 TEAEs were observed. 
Therefore, both modalities appeared tolerable. The safety of 
RFH therapy combined with chemotherapy has been reported 
in previous studies. In a trial on RFH therapy combined with 
weekly docetaxel in patients with locally advanced non‑small 
cell lung cancer, grade 3 or 4 neutropenia occurred in only 24% 
of the patients (18). In a randomized trial comparing RFH plus 
chemotherapy with chemotherapy alone in advanced ovarian 
cancer, toxicity was similar between arms (2). Collectively, 
these findings and the results of the current trial indicated that 
mEHT therapy may be safely combined with chemotherapy.
To the best of our knowledge, no study has reported 
superiority of RFH with chemotherapy over chemotherapy 
alone in the treatment of platinum‑resistant ovarian cancer. 
In the present study, mEHT therapy combined with weekly 
chemotherapy showed intermediate efficacy. Of the 9 patients, 
only 1 partial response was confirmed (response rate, 11%). 
Response based on CA125 was observed in 2 of 9 patients (22%). 
All responses were observed in the cisplatin arm. Specifically, 
in the cisplatin arm, 1 of 4 patients with measurable disease 
responded (response rate, 25%), and 2 of 5 patients with 
elevated baseline CA125 levels exhibited CA125 response 
(40%). This suggests that when combined with mEHT, 
while cisplatin appeared to be slightly more toxic, it was 
also more efficacious than paclitaxel. Supporting the present 
results, previous cell line studies suggested that hyperthermia 
enhanced the cytotoxicity of cisplatin but inhibited that of 
paclitaxel (12,13,19,20). Thus, mEHT therapy combined 
with weekly cisplatin administration should be considered a 
regimen for further investigation.
Of note, one radiologically confirmed partial response and 
two CA125 responses were observed in the present study in 
platinum‑resistant patients in the cisplatin arm. A single‑arm 
trial testing the efficacy of oral etoposide plus weekly cisplatin 
reported a 46% response rate in platinum‑resistant patients and 
high‑dose intensity achieved by weekly dosing was suggested 
as a mechanism for overcoming platinum resistance (21). Both 
weekly dosing and synergy between cisplatin and mEHT may 
be the mechanisms accountable for the responses observed in 
the present study.
The present study has certain limitations. First, the safety 
of therapy was determined using data from only 6 patients per 
group. Therefore, the safety of therapy should be considered 
preliminary and only be used to make decisions for further 
investigations. As another limitation, the present trial did 
not test multiple dose levels and did not investigate the 
Table III. Treatment‑emergent adverse events in the cisplatin arm.
Type Grade 1 Grade 2 Grade 3 Sum
Abdominal pain 1 1 0 2
Anemia 0 0 1 1
Anorexia 0 1 0 1
Back pain 1 1 0 2
Dizziness 0 1 0 1
Dry mouth 0 1 0 1
Dyspepsia 1 0 0 1
Edema face 1 0 0 1
Fatigue 1 0 0 1
Gastrointestinal pain 1 0 0 1
Headache 2 0 0 2
Mucositis oral 1 0 0 1
Nausea 2 1 1 4
Neutrophil count decreased 2 2 1 5
Periodontal disease 1 0 0 1
Peripheral sensory neuropathy 1 1 0 2
Platelet count decreased 0 1 1 2
Productive cough 1 0 0 1
Skin and subcutaneous tissue disorders‑others 1 0 0 1
Skin hyperpigmentation 0 1 0 1
Superficial thrombophlebitis 0 1 0 1
Telangiectasia 1 0 0 1
Vomiting 1 0 0 1
Sum 19 12 4 35
Patients who experienced multiple treatment‑emergent adverse events were counted more than one time.
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maximum tolerated dose of mEHT. This may have resulted 
in undertreatment. However, a recent study indicated that the 
optimal dose of mEHT in the treatment of recurrent ovarian 
cancer is 150 W for 1 h (7), and that dose is similar to the 
energy used in the present study (140 W). Nevertheless, a 
strength of the present study was that it was a multi‑center 
study.
Our group is planning a subsequent phase 2 trial, testing 
the efficacy and safety of weekly cisplatin plus mEHT for 
recurrent ovarian cancer, and efficacy will be evaluated in 
platinum‑sensitive and ‑resistant subgroups separately.
In conclusion, mEHT therapy with weekly paclitaxel 
or cisplatin appeared safe in female patients with recurrent 
or persistent epithelial ovarian, fallopian tube, or primary 
peritoneal carcinoma, thus warranting further investigation in 
clinical trials.
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